Pasithea Therapeutics (KTTA) EPS (Weighted Average and Diluted) (2021 - 2026)
Pasithea Therapeutics recorded quarterly EPS (Weighted Average and Diluted) of -$0.12 in Q1 2026, up 86.52% quarter-over-quarter from -$0.89 in Q4 2025, and up 92.55% year-over-year from -$0.06 in Q1 2025.
Pasithea Therapeutics' EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$0.12 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 92.55% year-over-year to -$0.12; the TTM figure through Mar 2026 stood at -$2.08 (up 80.38% YoY), while the FY2025 annual figure was -$2.91, up 77.07% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.12 for Q1 2026 at Pasithea Therapeutics, up from -$0.89 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.01 in Q1 2022 to a low of -$8.98 in Q4 2022.
- A 5-year average of -$2.26 and a median of -$2.41 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) plunged 18269.45% in 2023 and jumped 92.55% in 2026, its largest moves.
- Pasithea Therapeutics' EPS (Weighted Average and Diluted) stood at -$8.98 in 2022, then soared by 49.78% to -$4.51 in 2023, then surged by 46.56% to -$2.41 in 2024, then surged by 63.07% to -$0.89 in 2025, then soared by 86.52% to -$0.12 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.12, -$0.89, and -$0.41 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | -0.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.12 |
| Dec 31, 2025 | -0.89 |
| Sep 30, 2025 | -0.41 |
| Jun 30, 2025 | -0.66 |
| Mar 31, 2025 | -1.61 |
| Dec 31, 2024 | -2.41 |
| Sep 30, 2024 | -2.87 |
| Jun 30, 2024 | -3.71 |
| Mar 31, 2024 | -3.70 |
| Dec 31, 2023 | -4.51 |
| Sep 30, 2023 | -2.87 |
| Jun 30, 2023 | -2.75 |
| Mar 31, 2023 | -2.60 |
| Dec 31, 2022 | -8.98 |
| Sep 30, 2022 | -0.16 |
| Jun 30, 2022 | -0.09 |
| Mar 31, 2022 | -0.01 |
| Dec 31, 2021 | 0.06 |
| Sep 30, 2021 | -0.18 |
| Jun 30, 2021 | -0.09 |